About
Behçet’s syndrome is a rare, multisystem inflammatory disease with a relapsing and remitting course and highly variable organ involvement, ranging from mucocutaneous and joint manifestations to severe ocular, vascular, neurologic, or gastrointestinal disease.
The OMERACT Behçet’s Syndrome Working Group advances domain measurement for clinical trials in this complex condition. The group developed and secured endorsement of an OMERACT core domain set that includes mandatory domains for all trials—disease activity, new organ involvement, quality of life, adverse events, and death—alongside organ-specific subdomains for particular manifestations.
Current Stage in the OMERACT Process
After establishing its Core Domain Set, the group is now selecting instruments to measure disease activity and quality of life. They are also developing a Behçet’s-specific quality of life index to better capture patient experiences.
Latest Update
OMERACT 2025 Conference Highlights
Fellow Poster: Our OMERACT Fellow, Berçemhan Sulu, presented a poster summarizing the current state of our work, sparking excellent conversations about next steps and collaborations. 👉 View the poster here
Lightning Talk: In a rapid-fire session, our team shared an upcoming teaser of the Special Interest Group (SIG) session taking place during the conference. 👉 Watch the lightning talk here
Closing Plenary Talk: We were also featured in the Closing Plenary, where we highlighted the activities of the (SIG). 👉 Watch the presentation here
OMERACT Endorsed Core Domain Set for Behçet’s Syndrome
